Interactive Decision Support Tool: Expert Guidance for the Treatment of Metastatic CRC
  • CME

LAUNCH TOOL
ACCEPT DISCLAIMER AND LAUNCH TOOL
Use this Interactive Decision Support Tool to compare your choice of therapy for patients with metastatic colorectal cancer with those of 5 renowned experts.
Tanios Bekaii-Saab
Tanios Bekaii-Saab, MD, FACP
George A. Fisher, MD, PhD
Axel Grothey Headshot
Axel Grothey, MD
Scott Kopetz, MD, PhD, FACP
John L. Marshall, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: August 26, 2019 Expiration: August 25, 2020

Disclaimer

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: Expert Guidance for the Treatment of Metastatic CRC,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices for treating patients with metastatic colorectal cancer. The information provided is based on expert guidance from Tanios Bekaii-Saab, MD, FACP; George A. Fisher, MD, PhD; Axel Grothey, MD; Scott Kopetz, MD, PhD, FACP; and John L. Marshall, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the Expert Guidance for the Treatment of Metastatic CRC Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2019 Clinical Care Options, LLC. All rights reserved.

Interactive Decision Support Tool
Expert Guidance for mCRC
LAUNCH TOOL
ACCEPT DISCLAIMER AND LAUNCH TOOL

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select optimal therapies for patients with mCRC based on patient-specific and disease-specific characteristics, including results of biomarker and genetic assessment
  • Apply latest clinical findings and guidelines to treatment selection for patients with mCRC who have progressed after second and later lines of therapy
  • Counsel patients to understand their treatment options and to be proactive, knowledgeable participants in their care

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Tanios Bekaii-Saab, MD, FACP

Professor
Mayo Clinic College of Medicine and Science
Leader, GI Cancer Program
Mayo Clinic Center
Consultant
Mayo Clinic in Arizona
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has disclosed that he has received consulting fees from AbbVie, Armo, Immuneering, Imugene, and Sillajen.
George A. Fisher, MD, PhD

Professor of Medicine
Department of Medicine/Oncology
Stanford University School of Medicine
Stanford, California

George A. Fisher, MD, PhD, has disclosed that he has received consulting fees from Jounce, Merck, Roche/Genentech, and Terumo, and funds for research support from Aduro, Merck, Forty Seven, and Roche/Genentech.
Axel Grothey, MD

Consultant
West Clinic
Memphis, Tennessee

Axel Grothey, MD, has disclosed that he has received consulting fees from Array, Bayer, Genentech, and Ipsen and funds for research support from Array, Bayer, Daiichi, and Genentech.
Scott Kopetz, MD, PhD, FACP

Associate Professor
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Scott Kopetz, MD, PhD, FACP, has disclosed that he has received consulting fees from Amal, Amgen, Biocartics, EMD Serono, Genentech, Holy Stone, Karyopharm, Merck, Navire, Novartis, Roche, and Symphogen and has ownership interest (less than 5%) in MolecularMatch and Navire.
John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees, fees for non-CME/CE services, and funds for research support from Amgen, Bayer, Celgene, Genentech, Merck, and Taiho.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Scientific Director

Krista Marcello has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with metastatic colorectal cancer.

Goal

The goal of this activity is to improve participants’ competence in applying the latest practice-changing data in the individualized clinical management of patients with metastatic colorectal cancer.

Accreditation

Joint Accreditation Statement

 

In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 26, 2019, through August 25, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Enter patient details and submit case.
4. Review the patient case online or printed out.
5. Submit answers to the Clinical Implications questions and evaluation questions online.

You must respond to all Clinical Implications and evaluation questions to receive credit. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Enter the characteristics of your patient with pancreatic cancer into this online tool from Clinical Care Options to see therapeutic recommendations from 5 experts.

Andrew H. Ko, MD
Program Director
Elena Gabriela Chiorean, MD Dan Laheru, MD Michael J. Pishvaian, MD, PhD Andrea Wang-Gillam, MD, PhD
Released: September 12, 2019

In this slideset, Sanjay Mukhopadhyay, MD, reviews the optimal application of PD-L1 testing to predict response to checkpoint inhibitors in lung cancer.

person default Sanjay Mukhopadhyay, MD Released: September 11, 2019

In this slideset, Sandip P. Patel, MD, reviews emerging predictors of response to checkpoint inhibitors in lung cancer.

Sandip P. Patel, MD Released: September 11, 2019

In this slideset, H. Jack West, MD, reviews the latest clinical data supporting the optimal use of checkpoint inhibitor therapy across lung cancer.

H. Jack West, MD Released: September 10, 2019
Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Produced in collaboration with
Grace Logo
Supported by educational grants from
Amgen
Bayer Healthcare Pharmaceuticals Inc.
Taiho Oncology Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?